Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02053935 · ClinicalTrials.gov registry record · Phase 1
Impact of Dopamine Infusion on Insulin Secretion in Healthy Subjects
A Phase 1 study, sponsored by Albert Einstein College of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02053935 is a Phase 1 study that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 15 participants.
The verdict
NCT02053935, a Phase 1 study, has completed, sponsored by Albert Einstein College of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a clinical study of a drug named dopamine and how it affects our bodies ability to make and secrete insulin. Insulin is a hormone made in the pancreas that helps our body regulate sugar levels. We think that this drug decreases the amount of insulin our body makes and causes our sugar levels to be high. When you are critically ill there can be many adverse effects if you have sugar levels that are too high.
Interventions
- DRUG Dopamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2013-12 |
| Est. Completion | 2016-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02053935
The ClinicalTrials.gov registry entry for NCT02053935 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Albert Einstein College of Medicine, which has 175 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dopamine is the first listed.
NCT02053935 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02053935 about?
NCT02053935 is a clinical study titled "Impact of Dopamine Infusion on Insulin Secretion in Healthy Subjects". This is a clinical study of a drug named dopamine and how it affects our bodies ability to make and secrete insulin. Insulin is a hormone made in the pancreas that helps our body regulate sugar levels. We think that this drug decreases the amount of insulin our body makes and causes our sugar levels...
What is the current status of trial NCT02053935?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2013-12. Estimated completion is 2016-01.
What interventions are being tested in trial NCT02053935?
The interventions under investigation include: Dopamine (DRUG).
Who is sponsoring clinical trial NCT02053935?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.